Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

Oslo, Norway, 19 February 2024: Photocure ASA (Photocure, PHO: OSE) will
announce the fourth quarter and preliminary full year 2023 financial results on
Wednesday 21 February 2024 at 08:00 CET and will present a live webcast at 14:00
CET the same day.

The quarterly report and presentation will be published at 08:00 CET and will be
publicly available at www.photocure.com.

The investor presentation will be streamed live and be hosted by Dan Schneider,
CEO and Erik Dahl, CFO. The presentation will be held in English and questions
can be submitted throughout the event. The presentation is scheduled to conclude
at 14:45 CET.

The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20240221_5/ (https://eur01.
safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandi
ngpage%2Fhegnarmedia%2F20240221_5%2F&data=05%7C02%7CTH%40photocure.no%7C3927bf824
64f41ac7d5308dc30b85f71%7C0986794f1d6f488980bd853c0715d3c1%7C0%7C0%7C638438815640
946018%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haW
wiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=vXoPi76on8Das0VeVb8BAkEiYBgnwtw0L9d3rf%2F66BY
%3D&reserved=0)

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.